Eric J. Topol

TL;DR: Blockage of the platelet glycoprotein IIb/IIIa receptor reduces ischemic complications when used as an adjunct to percutaneous coronary intervention or the management of acute isChemic syndromes.

TL;DR: Findings indicate that RAGE/ligand interaction plays a key role in neointimal formation after vascular injury irrespective of diabetes status and suggest a novel target to minimize neointedimal hyperplasia.

TL;DR: Lower aspirin doses (75 to 81 mg/d) may optimize efficacy and safety for patients requiring aspirin for long-term prevention, especially those taking clopidogrel, according to post hoc analysis of associations between investigator-determined daily aspirin dose and thrombotic and hemorrhagic outcomes in the prospective CHARISMA trial.

TL;DR: The procedural outcome of rotational atherectomy is highly correlated with stenosis morphology and location and sex of the patient, and overall outcome with the Rotablator appears to be similar to that with balloon angioplasty and other competing techniques.

TL;DR: Lotrafiban, an orally administered platelet glycoprotein IIb/IIIa blocker, induced a 33% increase in death rate, which was vascular in origin and not affected by the type of atherosclerotic involvement at entry to the trial.